Advertisement

LncRNA ATP1A1-AS1 inhibits cell proliferation and promotes cell apoptosis in thyroid carcinoma by regulating the miR-620/IRF2BP2 axis

  • Author Footnotes
    1 The first two authors, Jintang Jia, MD, and Yipeng Liu, MM, contributed equally to the work.
    Jintang Jia
    Footnotes
    1 The first two authors, Jintang Jia, MD, and Yipeng Liu, MM, contributed equally to the work.
    Affiliations
    Department of General Surgery, Gansu Provincial Maternity and Child-care Hospital, Lanzhou 730050, Gansu, China
    Search for articles by this author
  • Yipeng Liu
    Affiliations
    Graduate School, Northwest Minzu University, Lanzhou 730030, Gansu, China
    Search for articles by this author
  • Xiaogang Yang
    Affiliations
    Department of General Surgery, Gansu Provincial Maternity and Child-care Hospital, Lanzhou 730050, Gansu, China
    Search for articles by this author
  • Zhiqiang Wu
    Affiliations
    Department of General Surgery, Gansu Provincial Maternity and Child-care Hospital, Lanzhou 730050, Gansu, China
    Search for articles by this author
  • Xingwen Xu
    Affiliations
    Department of General Surgery, Gansu Provincial Maternity and Child-care Hospital, Lanzhou 730050, Gansu, China
    Search for articles by this author
  • Fugui Kang
    Affiliations
    Department of General Surgery, Gansu Provincial Maternity and Child-care Hospital, Lanzhou 730050, Gansu, China
    Search for articles by this author
  • Author Footnotes
    1 The first two authors, Jintang Jia, MD, and Yipeng Liu, MM, contributed equally to the work.
    Yifan Liu
    Correspondence
    Corresponding author at: Yifan Liu, The Second Hospital of Lanzhou University, No.143, Qilihebei Street, Qilihe District, Lanzhou, Gansu, China.
    Footnotes
    1 The first two authors, Jintang Jia, MD, and Yipeng Liu, MM, contributed equally to the work.
    Affiliations
    Department of Endocrinology, The Second Hospital of Lanzhou University, Lanzhou 730030, Gansu, China
    Search for articles by this author
  • Author Footnotes
    1 The first two authors, Jintang Jia, MD, and Yipeng Liu, MM, contributed equally to the work.
Published:August 21, 2022DOI:https://doi.org/10.1016/j.amjms.2022.08.005

      Abstract

      Background

      Thyroid carcinoma (THCA) is a common malignancy of the endocrine system. Further understanding of the molecular mechanism underlying THCA is crucial to develop effective diagnostic therapy and improve its treatments. In this study, we intended to provide novel direction for THCA targeted therapy from the aspect of lncRNA-miRNA-mRNA interaction. We aimed to investigate the function and molecular mechanism of lncRNA ATP1A1-AS1 in THCA.

      Methods

      Gene expression was assessed by reverse transcription quantitative polymerase chain reaction (RT-qPCR). Cell growth was detected by CCK-8 and EdU assays. Flow cytometry was applied for analyzing cell apoptosis. The binding of ATP1A1-AS1 or IRF2BP2 to miR-620 was validated by RNA pulldown and luciferase reporter assays. The protein levels were examined by western blotting.

      Results

      ATP1A1-AS1 was decreased in THCA cells and tissues. ATP1A1-AS1 overexpression attenuated cell growth and promoted apoptosis. MiR-620, which was upregulated in THCA, was identified as a direct target of ATP1A1-AS1. Furthermore, IRF2BP2 was discovered to be a target of miR-620, which displayed low expression in THCA cells and tissues. Importantly, IRF2BP2 knockdown reversed the influence of ATP1A1-AS1 overexpression on THCA cell proliferation and apoptosis.

      Conclusions

      LncRNA ATP1A1-AS1 inhibited cell growth and promotes apoptosis in THCA via the miR-620/IRF2BP2 axis.

      Key Indexing Terms

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Liu Y
        • Liao L
        • An C
        • et al.
        α-Enolase lies downstream of mTOR/HIF1α and promotes thyroid carcinoma progression by regulating CST1.
        Front Cell Dev Biol. 2021; 9670019
        • Roman BR
        • Morris LG
        • Davies L
        The thyroid cancer epidemic, 2017 perspective.
        Curr Opin Endocrinol Diabetes Obes. 2017; 24: 332-336
        • Deng Y
        • Li H
        • Wang M
        • et al.
        Global burden of thyroid cancer from 1990 to 2017.
        JAMA Netw Open. 2020; 3e208759
        • Yildirim Simsir I
        • Cetinkalp S
        • Kabalak T
        Review of factors contributing to nodular goiter and thyroid carcinoma.
        Med Princ Pract. 2020; 29: 1-5
        • Lloyd RV
        • Buehler D
        • Khanafshar E
        Papillary thyroid carcinoma variants.
        Head Neck Pathol. 2011; 5: 51-56
        • Prete A
        • Borges de Souza P
        • Censi S
        • et al.
        Update on fundamental mechanisms of thyroid cancer.
        Front Endocrinol. 2020; 11: 102
        • Sessions RB
        • Davidson BJ
        Thyroid cancer.
        Med Clin North Am. 1993; 77: 517-538
        • Cabanillas ME
        • McFadden DG
        • Durante C
        Thyroid cancer.
        Lancet. 2016; 388: 2783-2795
        • Hernando J
        • Ros J
        • Arroyo A
        • et al.
        Clinical and translational challenges in thyroid cancer.
        Curr Med Chem. 2020; 27: 4806-4822
        • Raue F
        • Frank-Raue K
        Thyroid cancer: risk-stratified management and individualized therapy.
        Clin Cancer Res. 2016; 22: 5012-5021
        • Mellis D
        • Caporali A
        MicroRNA-based therapeutics in cardiovascular disease: screening and delivery to the target.
        Biochem Soc Trans. 2018; 46: 11-21
        • Iorio MV
        • Croce CM
        MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review.
        EMBO Mol Med. 2012; 4: 143-159
        • Zhang Z
        • Xiao Q
        • Li X
        MicroRNA-574-5p directly targets FOXN3 to mediate thyroid cancer progression via Wnt/β-catenin signaling pathway.
        Pathol Res Pract. 2020; 216152939
        • Bian S
        miR-4319 inhibited the development of thyroid cancer by modulating FUS-stabilized SMURF1.
        J Cell Biochem. 2020; 121: 174-182
        • Gu L
        • Sun W
        MiR-539 inhibits thyroid cancer cell migration and invasion by directly targeting CARMA1.
        Biochem Biophys Res Commun. 2015; 464: 1128-1133
        • Wu C
        • Zhao A
        • Tan T
        • et al.
        Overexpression of microRNA-620 facilitates the resistance of triple negative breast cancer cells to gemcitabine treatment by targeting DCTD.
        Exp Ther Med. 2019; 18: 550-558
        • Zhao Z
        • Han C
        • Liu J
        • et al.
        GPC5, a tumor suppressor, is regulated by miR-620 in lung adenocarcinoma.
        Mol Med Rep. 2014; 9: 2540-2546
        • Long R
        • Liu Z
        • Li J
        • et al.
        HCG11 up-regulation induced by ELK4 suppressed proliferation in vestibular schwannoma by targeting miR-620/ELK4.
        Cancer Cell Int. 2021; 21: 5
        • Thin KZ
        • Tu JC
        • Raveendran S
        Long non-coding SNHG1 in cancer.
        Clin Chim Acta. 2019; 494: 38-47
        • Bhan A
        • Soleimani M
        • Mandal SS
        Long noncoding RNA and cancer: a new paradigm.
        Cancer Res. 2017; 77: 3965-3981
        • Renganathan A
        • Felley-Bosco E
        Long noncoding RNAs in cancer and therapeutic potential.
        Adv Exp Med Biol. 2017; 1008: 199-222
        • Peng WX
        • Koirala P
        • Mo YY
        LncRNA-mediated regulation of cell signaling in cancer.
        Oncogene. 2017; 36: 5661-5667
        • Li Z
        • Gao B
        • Hao S
        • et al.
        Knockdown of lncRNA-PANDAR suppresses the proliferation, cell cycle and promotes apoptosis in thyroid cancer cells.
        Excli j. 2017; 16: 354-362
        • Liu H
        • Deng H
        • Zhao Y
        • et al.
        LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling.
        J Exp Clin Cancer Res. 2018; 37: 279
        • Shen Y
        • Xia E
        • Bhandari A
        • et al.
        LncRNA PROX1-AS1 promotes proliferation, invasion, and migration in papillary thyroid carcinoma.
        Biosci Rep. 2018; 38
        • Fan X
        • Ashraf UM
        • Drummond CA
        • et al.
        Characterization of a long non-coding RNA, the antisense RNA of Na/K-ATPase α1 in human kidney cells.
        Int J Mol Sci. 2018; 19
        • Jiang Y
        • Gou X
        • Wei Z
        • et al.
        Bioinformatics profiling integrating a three immune-related long non-coding RNA signature as a prognostic model for clear cell renal cell carcinoma.
        Cancer Cell Int. 2020; 20: 166
        • Rao Y
        • Liu H
        • Yan X
        • et al.
        In silico analysis identifies differently expressed lncRNAs as novel biomarkers for the prognosis of thyroid cancer.
        Comput Math Methods Med. 2020; 20203651051
        • Li G
        • Kong Q
        LncRNA LINC00460 promotes the papillary thyroid cancer progression by regulating the LINC00460/miR-485-5p/Raf1 axis.
        Biol Res. 2019; 52: 61
        • Feng J
        • Zhou Q
        • Yi H
        • et al.
        A novel lncRNA n384546 promotes thyroid papillary cancer progression and metastasis by acting as a competing endogenous RNA of miR-145-5p to regulate AKT3.
        Cell Death Dis. 2019; 10: 433
        • Zhuang X
        • Tong H
        • Ding Y
        • et al.
        Long noncoding RNA ABHD11-AS1 functions as a competing endogenous RNA to regulate papillary thyroid cancer progression by miR-199a-5p/SLC1A5 axis.
        Cell Death Dis. 2019; 10: 620
        • Diesen DL
        • Skinner MA
        Pediatric thyroid cancer.
        Semin Pediatr Surg. 2012; 21: 44-50
        • Saravana-Bawan B
        • Bajwa A
        • Paterson J
        • et al.
        Active surveillance of low-risk papillary thyroid cancer: a meta-analysis.
        Surgery. 2020; 167: 46-55
        • Fan CN
        • Ma L
        • Liu N
        Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer.
        J Transl Med. 2018; 16: 264
        • Zucchelli S
        • Cotella D
        • Takahashi H
        • et al.
        SINEUPs: A new class of natural and synthetic antisense long non-coding RNAs that activate translation.
        RNA Biol. 2015; 12: 771-779
        • Faghihi MA
        • Wahlestedt C
        Regulatory roles of natural antisense transcripts.
        Nat Rev Mol Cell Biol. 2009; 10: 637-643
        • Strausberg RL
        • Feingold EA
        • Grouse LH
        • et al.
        Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.
        Proc Natl Acad Sci U S A. 2002; 99: 16899-16903
        • Paraskevopoulou MD
        • Hatzigeorgiou AG
        Analyzing MiRNA-LncRNA interactions.
        Methods Mol Biol. 2016; 1402: 271-286
        • Li X
        • Shen M
        Circular RNA hsa_circ_103809 suppresses hepatocellular carcinoma proliferation and invasion by sponging miR-620.
        Eur Rev Med Pharmacol Sci. 2019; 23: 555-566
        • Tian JDC
        • Liang L
        Involvement of circular RNA SMARCA5/microRNA-620 axis in the regulation of cervical cancer cell proliferation, invasion and migration.
        Eur Rev Med Pharmacol Sci. 2018; 22: 8589-8598
        • Ramalho-Oliveira R
        • Oliveira-Vieira B
        • Viola JPB
        IRF2BP2: A new player in the regulation of cell homeostasis.
        J Leukoc Biol. 2019; 106: 717-723
        • Yao Y
        • Wang Y
        • Li L
        • et al.
        Down-regulation of interferon regulatory factor 2 binding protein 2 suppresses gastric cancer progression by negatively regulating connective tissue growth factor.
        J Cell Mol Med. 2019; 23: 8076-8089
        • Feng X
        • Lu T
        • Li J
        • et al.
        The tumor suppressor interferon regulatory factor 2 binding protein 2 regulates hippo pathway in liver cancer by a feedback loop in mice.
        Hepatology. 2020; 71: 1988-2004